Explore groundbreaking gene-editing therapy for kidney disease, offering hope to those with polycystic kidney disease.

Mayo Clinic researchers have developed a promising gene-editing therapy that directly corrects a genetic mutation responsible for autosomal dominant polycystic kidney disease (ADPKD), the most common ...

The disease leads to the progressive growth of fluid-filled cysts in the kidneys, often resulting in kidney failure and other ...

Dapagliflozin improved eGFR slope in patients with CKD associated with ADPKD, but it resulted in an increase in kidney volume. Dapagliflozin may exert a protective effect on kidney function in ...

A large study of patients in the US Veterans Administration health system revealed that patients with ADPKD had a much higher rates of chronic obstructive pulmonary disease, hypertension, diabetes, ...

The Kidney Disease: Improving Global Outcomes (KDIGO) group has released its 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney ...

(StatePoint) This article is sponsored by Otsuka America Pharmaceutical, Inc. Each year, September 4 marks Polycystic Kidney Disease (PKD) Awareness Day, an initiative that aims to increase public ...

U.S.-based researchers examined the burden of imaging in a population of patients with ADPKD, versus that of patients with chronic kidney disease (CKD). People with ADPKD underwent more abdominal ...

Jul 14, 2025, 5:41am CDT Updated: Jul 14, 2025, 6:26am CDT Courtesy of Renasant Renasant Bio CEO Emily Conley From the San Francisco Business Times. Patients with a life-threatening genetic kidney ...

The researchers found that preoperative hypertension, dialysis, and steroid use were most common. HealthDay News – Major complications occur in 7.0% of patients undergoing nephrectomy with a diagnosis ...